Table 1: Principal metabolic syndrome definitions.

WHO (1999) EGIR (1999) NCEP ATP III (2001)

Fasting plasma glucoseGlucose intolerance, IGT or diabetes, and/or insulin resistance together with two or more of the following:Insulin resistance (defined as hyperinsulinemia—top 25% or fasting insulin values among the nondiabetic population). Plus two of the following: 3 or more of the following factors:
≥6.1 mmol/L (110 mg/dl) but nondiabetic5.6 mmol/L (100 mg/dl)

Blood pressure>140/90 mmHg ≥140/90 mmHg or treatment ≥130/≥ 85 mmHg

TriglyceridesRaised plasma triglycerides
≥1.7 mmol/L (150 mg/dl)
and/or
(i) 2.0 mmol/L (178 mg/dl) or treatment and/or 1.7 mmol/L (150 mg/dl)

HDL-cholesterolMen: <0.9 mmol/L (35 mg/dl) Women: <1.0 mmol/L (39 mg/dl) <1.0 mmol/L (39 mg/dl) or treatmentMen: <1.03 mmol/L (40 mg/dl)
Women: <1.29 mmol/L (50 mg/dl)

ObesityMen: waist-hip ratio >0.90
Women: waist-hip ratio >0.85
and/or BMI >30 Kg/2
Men: waist circumference ≥ 94 cm Women: waist circumference ≥80 cm Men: waist circumference >102 cm
Women waist circumference >88 cm

MicroalbuminuriaUrinary albumin excretion rate
≥ 20  𝜇 g/min or albumin:
creatinine ratio ≥30 mg/g

WHO:World Health Organization; EGIR: European Group for the Study of Insulin Resistance; NCEP/ATPIII: National Cholesterol Education Program's Adult Treatment Panel III.